RA Capital Management portfolio · Q3 2026
RA Capital Management, L.P. · CIK 0001346824 ·13F filings on SEC EDGAR
In Q3 2026, RA Capital Management, L.P. reported 92 positions worth $10B. Its largest holding was ASND at 23.5% of the portfolio, and the top 10 made up 61%. Its largest new position was FRNM ($242M), and it sold out of BCRX.
- NEW 21
- ADD 6
- REDUCE 13
- EXIT 13
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 52 positions are grouped as one box.
Portfolio history
Q4 2025 to Q3 2026, 4 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
ASND ASCENDIS PHARMA A/S | 23.50% | $266.72 | $227.83 | -14.6% | $2.3B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PBLS PARABILIS MEDICINES INC | 9.45% | $27.41 | $32.29 | +17.8% | $942.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCVX VAXCYTE INC | 6.55% | $41.48 | $56.90 | +37.2% | $652.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 6.37% | $39.80 | $95.22 | +139.3% | $634.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 3.42% | $17.65 | $40.60 | +130.0% | $340.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TYRA TYRA BIOSCIENCES INC | 2.68% | $16.19 | $21.87 | +35.1% | $266.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 2.43% | $15.75 | $15.75 | 0.0% | $242M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COAG HEMAB THERAPEUTICS HOLDINGS | 2.42% | $36.73 | $30.84 | -16.0% | $240.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMS NEWAMSTERDAM PHARMA CO NV | 2.33% | $13.79 | $24.32 | +76.4% | $232.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 2.16% | $22.90 | $39.13 | +70.9% | $215.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGP SPYGLASS PHARMA INC | 2.09% | $25.91 | $26.00 | +0.3% | $208.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JANX JANUX THERAPEUTICS INC | 1.94% | $27.51 | $17.28 | -37.2% | $193.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLYS MINERALYS THERAPEUTICS INC | 1.94% | $19.05 | $25.13 | +31.9% | $193.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRON DISC MEDICINE INC | 1.61% | $57.26 | $65.46 | +14.3% | $160.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 1.49% | $3.19 | $4.87 | +52.6% | $148.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCAX BICARA THERAPEUTICS INC | 1.35% | $25.24 | $18.61 | -26.3% | $135M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARTV ARTIVA BIOTHERAPEUTICS INC | 1.32% | $12.69 | $7.12 | -43.9% | $131.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 1.32% | $12.35 | $24.95 | +102.0% | $131.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 1.30% | $95.17 | $83.29 | -12.5% | $129.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 1.25% | $29.10 | $29.10 | 0.0% | $124.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLYM CLIMB BIO INC | 1.17% | $11.66 | $11.47 | -1.6% | $116.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 1.02% | $133.26 | $99.02 | -25.7% | $102M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WVE WAVE LIFE SCIENCES INC | 1.00% | $3.70 | $3.70 | 0.0% | $99.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LTGO LATIGO BIOTHERAPEUTICS INC | 0.89% | $16.70 | $16.70 | 0.0% | $88.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLDB SOLID BIOSCIENCES INC | 0.87% | $7.48 | $7.23 | -3.3% | $87M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VOR VOR BIOPHARMA INC | 0.86% | $22.85 | $19.08 | -16.5% | $85.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LBRX LB PHARMACEUTICALS INC | 0.85% | $17.05 | $38.38 | +125.0% | $84.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GHRS GH RESEARCH PLC | 0.85% | $16.65 | $23.48 | +41.0% | $84.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OBX OBSIDIAN THERAPEUTICS INC | 0.82% | $13.73 | $13.73 | 0.0% | $81.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZLAB ZAI LAB LTD-ADR | 0.74% | $18.81 | $26.34 | +40.0% | $74.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FDMT 4D MOLECULAR THERAPEUTICS IN | 0.72% | $9.26 | $14.31 | +54.6% | $72.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRS ACLARIS THERAPEUTICS INC | 0.67% | $4.47 | $5.26 | +17.8% | $66.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SANA SANA BIOTECHNOLOGY INC | 0.55% | $3.49 | $2.92 | -16.5% | $54.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNPR MONOPAR THERAPEUTICS INC | 0.53% | $32.12 | $79.67 | +148.0% | $53.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GERN GERON CORP | 0.53% | $1.84 | $1.23 | -33.2% | $52.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DMRA DAMORA THERAPEUTICS INC | 0.51% | $21.28 | $21.28 | 0.0% | $51.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 0.49% | $8.06 | $2.42 | -70.0% | $48.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRY ARS PHARMACEUTICALS INC | 0.47% | $5.93 | $4.31 | -27.3% | $46.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABOS ACUMEN PHARMACEUTICALS INC | 0.47% | $8.62 | $2.22 | -74.2% | $46.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.43% | $11.76 | $11.76 | 0.0% | $43M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGEN AGENUS INC | 0.41% | $9.93 | $9.93 | 0.0% | $40.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RZLT REZOLUTE INC | 0.39% | $2.44 | $4.14 | +69.7% | $39.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 0.34% | $10.46 | $5.26 | -49.7% | $34M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SCTX SCRIBE THERAPEUTICS INC | 0.33% | $18.40 | $18.40 | 0.0% | $33.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IPSC CENTURY THERAPEUTICS INC | 0.30% | $2.26 | $1.71 | -24.3% | $30.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.29% | $17.18 | $8.26 | -51.9% | $28.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRSA KORSANA BIOSCIENCES INC | 0.29% | $32.00 | $32.00 | 0.0% | $28.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAPR CAPRICOR THERAPEUTICS INC | 0.29% | $7.22 | $9.47 | +31.3% | $28.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NKTX NKARTA INC | 0.28% | $21.10 | $2.62 | -87.6% | $28.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCCC C4 THERAPEUTICS INC | 0.27% | $1.94 | $3.33 | +71.3% | $27.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.26% | $13.86 | $14.05 | +1.4% | $25.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRLD PRELUDE THERAPEUTICS INC | 0.25% | $5.33 | $3.91 | -26.6% | $25.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACRV ACRIVON THERAPEUTICS INC | 0.25% | $6.77 | $2.05 | -69.7% | $25.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASMB ASSEMBLY BIOSCIENCES INC | 0.24% | $25.60 | $23.49 | -8.2% | $24M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EDIT EDITAS MEDICINE INC | 0.23% | $3.24 | $2.57 | -20.7% | $22.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QTTB Q32 BIO INC | 0.19% | $12.74 | $8.27 | -35.1% | $19.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 0.19% | $5.55 | $7.77 | +40.0% | $19.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ETRA ELECTRA THERAPEUTICS INC | 0.19% | $11.25 | $11.25 | 0.0% | $19M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALT ALTIMMUNE INC | 0.19% | $3.04 | $2.86 | -5.9% | $18.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTC BENITEC BIOPHARMA INC | 0.19% | $13.47 | $10.00 | -25.8% | $18.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALXO ALX ONCOLOGY HOLDINGS INC | 0.18% | $2.00 | $1.39 | -30.7% | $18.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGMT SAGIMET BIOSCIENCES INC-A | 0.18% | $9.88 | $9.88 | 0.0% | $17.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 0.17% | $9.93 | $3.38 | -66.0% | $16.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LENZ LENZ THERAPEUTICS INC | 0.16% | $22.33 | $3.84 | -82.8% | $16M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AURA AURA BIOSCIENCES INC | 0.16% | $7.10 | $6.28 | -11.5% | $15.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTX AVALO THERAPEUTICS INC | 0.15% | $12.53 | $15.33 | +22.4% | $15.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IKT INHIBIKASE THERAPEUTICS INC | 0.14% | $2.06 | $2.06 | 0.0% | $14.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENTX ENTERA BIO LTD | 0.14% | $2.91 | $2.91 | 0.0% | $14.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPTX SEAPORT THERAPEUTICS INC | 0.14% | $21.72 | $20.17 | -7.1% | $14.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.14% | $2.01 | $3.17 | +57.7% | $14M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OVID OVID THERAPEUTICS INC | 0.14% | $1.63 | $2.49 | +52.8% | $13.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.14% | $92.38 | $85.48 | -7.5% | $13.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
HLXC HELIX ACQUISITION CORP-CL A | 0.13% | $10.23 | $10.57 | +3.3% | $13.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.13% | $72.97 | $49.82 | -31.7% | $13.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRBP CORBUS PHARMACEUTICALS HOLDI | 0.13% | $6.82 | $6.82 | 0.0% | $13.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BRVE BRAVEHEART BIO INC | 0.11% | $20.20 | $20.20 | 0.0% | $11.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OKUR ONKURE THERAPEUTICS INC-A | 0.11% | $4.14 | $2.72 | -34.2% | $10.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.10% | $2.35 | $1.35 | -42.6% | $9.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INO INOVIO PHARMACEUTICALS INC | 0.09% | $1.22 | $1.22 | 0.0% | $8.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGNX MACROGENICS INC | 0.07% | $2.89 | $3.86 | +33.6% | $7.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RANI RANI THERAPEUTICS HOLDINGS-A | 0.07% | $1.35 | $0.79 | -41.4% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACET ADICET BIO INC | 0.07% | $8.10 | $7.14 | -11.9% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TCGX TCGX ACQUISITION CORP-A | 0.06% | $12.51 | $12.51 | 0.0% | $6.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FTH FAETH THERAPEUTICS INC | 0.06% | $25.00 | $29.74 | +19.0% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JATT JATT II ACQUISITION CORP | 0.06% | $11.36 | $11.18 | -1.6% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JTTT JATT III ACQUISITION CORP | 0.05% | $11.02 | $11.02 | 0.0% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMSW NEWAMSTERDAM PHARMA CO NV-27 | 0.04% | $0.87 | $12.65 | +1,356.9% | $4.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMAN AMANAT ACQUISITION CORP CL A | 0.04% | $10.16 | $10.67 | +5.0% | $4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EQ EQUILLIUM INC | 0.04% | $2.00 | $1.62 | -18.8% | $3.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.03% | $16.11 | $16.11 | 0.0% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STOK STOKE THERAPEUTICS INC | 0.02% | $26.00 | $26.00 | 0.0% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTN PALATIN TECHNOLOGIES INC | 0.01% | $15.38 | $8.87 | -42.3% | $551K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price.
Changes in shares
Change in shares held vs Jun 30, 2026, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Jun 30, 2026 and not reported for Q3 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| BCRX BIOCRYST PHARMACEUTICALS INC | 1.38% | 15,827,186 | $158.3M | EXIT |
| Y95308105 WAVE LIFE SCIENCES LTD | 1.36% | 26,975,505 | $156.7M | EXIT |
| NUVL NUVALENT INC-A | 1.34% | 1,246,456 | $153.9M | EXIT |
| NTLA INTELLIA THERAPEUTICS INC | 0.67% | 4,526,926 | $76.6M | EXIT |
| DFTX DEFINIUM THERAPEUTICS INC | 0.61% | 1,500,000 | $70.6M | EXIT |
| 36322Q206 DAMORA THERAPEUTICS INC | 0.54% | 2,399,702 | $62.4M | EXIT |
| AKTS AKTIS ONCOLOGY INC | 0.37% | 1,314,405 | $42.4M | EXIT |
| BIOA BIOAGE LABS INC | 0.36% | 1,671,648 | $41M | EXIT |
| KPTI KARYOPHARM THERAPEUTICS INC | 0.16% | 1,917,354 | $18.7M | EXIT |
| WAY WAYSTAR HOLDING CORP | 0.09% | 529,400 | $10.9M | EXIT |
| FRNM FREENOME INC | 0.07% | 750,000 | $8.2M | EXIT |
| CRVS CORVUS PHARMACEUTICALS INC | 0.06% | 450,000 | $6.7M | EXIT |
| HOWL WEREWOLF THERAPEUTICS INC | 0.01% | 2,387,744 | $859.3K | EXIT |
SEC filings for Q3 2026
- 13F-HR 0001104659-26-128411 · accepted Nov 16, 2026, 21:31 UTC